Patient-derived xenografts: a relevant preclinical model for drug development. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Pompili, Luca; Porru, Manuela; Caruso, Carla; Biroccio, Annamaria; Leonetti, Carlo
• Is Part Of: Journal of experimental & clinical cancer research. Volume 35:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: Patient-derived-xenografts -- Immunosuppressed mice -- Subcutaneous -- Orthotopic -- Tumor heterogeneity -- Predictive value; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s13046-016-0462-4
• Languages: English
• ISSNs: 1756-9966

Abstract

Abstract Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.